A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2018
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 14 Jan 2018 Planned number of patients changed from 40 to 48.
- 14 Jan 2018 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
- 14 Jan 2018 Status changed from not yet recruiting to recruiting.